Security Snapshot

BIOGEN INC. - Common Stock (BIIB) Institutional Ownership

CUSIP: 09062X103

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

987

Shares (Excl. Options)

139,684,462

Price

$175.99

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Type / Class
Equity / Common Stock
Symbol
BIIB on Nasdaq
Shares outstanding
146,919,278
Price per share
$176.37
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
139,684,462
Total reported value
$24,581,047,260
% of total 13F portfolios
0.01%
Share change
+8,248,118
Value change
+$1,492,071,909
Number of holders
987
Price from insider filings
$176.37
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • BIIB - BIOGEN INC. - Common Stock is tracked under CUSIP 09062X103.
  • 987 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 987 to 344 between Q4 2025 and Q1 2026.
  • Reported value moved from $24,581,047,260 to $1,335,298,218.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 987 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 09062X103?
CUSIP 09062X103 identifies BIIB - BIOGEN INC. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of BIOGEN INC. - Common Stock (BIIB) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PRIMECAP MANAGEMENT CO/CA/ 10% $2,094,853,956 14,954,697 PRIMECAP MANAGEMENT CO/CA/ 30 Sep 2025
BlackRock, Inc. 8.5% $1,502,927,856 12,506,681 BlackRock, Inc. 31 Mar 2025
VANGUARD CAPITAL MANAGEMENT LLC 7.5% $2,014,716,401 10,989,562 Vanguard Capital Management 31 Mar 2026
FMR LLC 6.4% $1,656,604,787 9,413,062 FMR LLC 31 Dec 2025
STATE STREET CORP 5% $1,025,549,213 7,321,168 STATE STREET CORPORATION 30 Sep 2025

As of 31 Dec 2025, 987 institutional investors reported holding 139,684,462 shares of BIOGEN INC. - Common Stock (BIIB). This represents 95% of the company’s total 146,919,278 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of BIOGEN INC. - Common Stock (BIIB) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 12% 17,447,092 +0.91% 0.04% $3,070,513,721
BlackRock, Inc. 10% 14,811,370 +0.32% 0.04% $2,606,652,919
PRIMECAP MANAGEMENT CO/CA/ 10% 14,757,997 -1.3% 2% $2,597,259,895
FMR LLC 6.4% 9,425,863 +632% 0.08% $1,658,857,459
STATE STREET CORP 4.9% 7,159,020 -2.2% 0.04% $1,259,915,930
GEODE CAPITAL MANAGEMENT, LLC 2.9% 4,199,399 +3.2% 0.05% $736,434,804
WELLINGTON MANAGEMENT GROUP LLP 2.4% 3,551,269 -16% 0.11% $624,987,832
Point72 Asset Management, L.P. 1.9% 2,813,192 -27% 0.78% $495,093,660
NORGES BANK 1.8% 2,638,834 0.05% $464,408,396
MORGAN STANLEY 1.6% 2,325,013 +3.3% 0.02% $409,179,635
JPMORGAN CHASE & CO 1.3% 1,857,262 +46% 0.02% $326,859,629
Boston Partners 1.2% 1,720,595 0.31% $302,815,433
Invesco Ltd. 1.1% 1,655,441 -32% 0.04% $291,341,046
AQR CAPITAL MANAGEMENT LLC 1% 1,528,616 -14% 0.14% $269,021,112
Legal & General Group Plc 0.99% 1,459,597 -8.4% 0.06% $256,874,480
NORTHERN TRUST CORP 0.98% 1,446,126 -3.5% 0.03% $254,503,714
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 0.95% 1,391,370 -3.3% 0.05% $244,867,205
BARCLAYS PLC 0.89% 1,305,007 -4% 0.09% $229,668,181
T. Rowe Price Investment Management, Inc. 0.8% 1,170,907 +9.7% 0.13% $206,068,000
Pacer Advisors, Inc. 0.78% 1,145,890 -21% 0.52% $201,665,181
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.78% 1,143,902 +1.8% 0.03% $201,315,313
BANK OF AMERICA CORP /DE/ 0.77% 1,128,845 -7.5% 0.01% $198,665,432
MILLENNIUM MANAGEMENT LLC 0.77% 1,125,586 +1.3% 0.14% $198,091,880
GOLDMAN SACHS GROUP INC 0.75% 1,099,366 +3.4% 0.03% $193,477,399
VAN ECK ASSOCIATES CORP 0.73% 1,065,616 -0.12% 0.15% $187,538,000

Institutional Holders of BIOGEN INC. - Common Stock (BIIB) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 7,309,855 $1,335,298,218 +$97,094,781 $183.33 344
2025 Q4 139,684,462 $24,581,047,260 +$1,492,071,909 $175.99 987
2025 Q3 131,083,249 $18,365,221,765 +$165,798,563 $140.08 894
2025 Q2 129,287,238 $16,238,624,437 +$284,309,412 $125.59 856
2025 Q1 127,028,107 $17,371,280,984 -$578,239,538 $136.84 865
2024 Q4 131,405,263 $20,085,982,511 +$272,768,825 $152.92 861
2024 Q3 128,615,457 $24,913,936,182 -$143,640,766 $193.84 903
2024 Q2 128,193,288 $29,710,612,652 -$84,741,446 $231.82 933
2024 Q1 128,518,741 $27,691,040,526 +$55,007,555 $215.63 932
2023 Q4 127,982,276 $33,111,816,739 +$901,376,761 $258.77 993
2023 Q3 124,470,870 $31,994,071,856 -$470,206,356 $257.01 954
2023 Q2 126,306,466 $35,966,219,806 +$277,366,431 $284.85 994
2023 Q1 125,053,711 $34,758,696,486 +$300,589,329 $278.03 987
2022 Q4 124,528,759 $34,492,440,417 +$242,887,240 $276.92 1,018
2022 Q3 123,323,995 $32,917,825,335 +$384,787,916 $267.00 966
2022 Q2 121,790,135 $24,840,540,438 -$152,960,663 $203.94 911
2022 Q1 122,616,063 $25,827,895,030 -$220,078,557 $210.60 941
2021 Q4 123,500,078 $29,628,123,955 -$101,746,917 $239.92 996
2021 Q3 123,461,166 $34,947,282,206 -$614,669,326 $282.99 1,026
2021 Q2 125,522,812 $43,460,004,330 -$566,581,701 $346.27 1,091
2021 Q1 127,388,312 $35,598,424,357 -$380,775,241 $279.75 1,079
2020 Q4 128,905,111 $31,559,604,046 -$521,085,738 $244.86 1,047
2020 Q3 130,781,613 $37,077,214,726 -$1,220,436,591 $283.68 1,036
2020 Q2 134,944,833 $36,078,566,447 -$2,622,299,974 $267.55 1,048
2020 Q1 144,371,093 $45,633,042,157 -$2,072,462,238 $316.38 1,090
2019 Q4 150,927,624 $44,753,934,396 -$2,257,146,159 $296.73 1,090
2019 Q3 159,069,579 $37,018,304,080 -$348,502,414 $232.82 972
2019 Q2 160,395,186 $37,502,672,698 -$2,138,732,747 $233.87 1,002
2019 Q1 171,326,218 $40,468,172,998 -$1,011,646,914 $236.38 1,071
2018 Q4 175,003,235 $52,619,725,529 -$839,325,018 $300.92 1,135
2018 Q3 177,270,767 $62,594,382,952 -$269,008,690 $353.31 1,140
2018 Q2 178,340,992 $51,731,992,582 -$2,444,250,744 $290.24 1,087
2018 Q1 186,913,555 $51,164,896,552 -$488,678,007 $273.82 1,096
2017 Q4 188,568,529 $60,044,982,772 +$9,889,834 $318.57 1,120
2017 Q3 188,385,830 $58,970,231,587 +$472,002,826 $313.12 1,011
2017 Q2 187,380,108 $50,837,222,531 +$288,984,209 $271.36 991
2017 Q1 188,211,491 $51,456,575,196 +$4,118,247,453 $273.42 1,016
2016 Q4 189,394,911 $53,679,916,033 -$1,015,070,941 $283.58 1,021
2016 Q3 191,778,014 $60,010,956,983 +$480,242,801 $313.03 1,007
2016 Q2 190,842,498 $46,263,524,155 -$112,555,041 $241.82 957
2016 Q1 190,858,170 $49,747,381,290 -$388,687,634 $260.32 938
2015 Q4 192,339,308 $59,013,396,053 -$2,589,949,247 $306.35 965
2015 Q3 200,266,975 $58,440,502,406 -$3,822,036,876 $291.81 914
2015 Q2 211,110,431 $85,274,602,341 -$1,015,846,158 $403.94 961
2015 Q1 213,693,704 $90,176,303,862 +$321,462,904 $422.24 961
2014 Q4 213,378,369 $72,452,156,965 -$502,527,627 $339.45 877
2014 Q3 214,442,358 $70,936,086,109 -$177,791,858 $330.81 811
2014 Q2 214,744,481 $67,717,564,176 +$911,109,846 $315.31 777
2014 Q1 212,004,121 $64,813,130,089 -$390,248,896 $305.87 767
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .